Clinical trials for Acute myelomonocytic leukemia
25 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc. · PI: Briggs Morrison, MD
- RECRUITINGPhase 2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny · PI: Leland Metheny, MD
- RECRUITINGPhase 2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong · PI: Harinder Gill, MD
- RECRUITINGPhase 1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group · PI: Alexandra M Stevens
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · PI: Xianmin Song, MD
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf · PI: Guido Kobbe, Prof. Dr.
- RECRUITINGPhase 1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR) · PI: John Pimanda, Professor
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center · PI: David Marin, MD
- RECRUITINGPhase 1NCT05233618Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Karen Ballen, MD · PI: Karen Ballen
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05428969A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesFaron Pharmaceuticals Ltd · PI: Mika Kontro, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT05584761Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAMLThe First Affiliated Hospital with Nanjing Medical University
- ACTIVE NOT RECRUITINGPhase 1NCT04891757FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesFoghorn Therapeutics Inc. · PI: Sarah Reilly, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04668885CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDSCase Comprehensive Cancer Center · PI: Sudipto Mukherjee, MD, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT04603001Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
- RECRUITINGPHASE1, PHASE2NCT04581512Study to Evaluate the Safety and Tolerability of EP0042Ellipses Pharma · PI: David Taussig
- RECRUITINGPHASE2, PHASE3NCT04256317A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)Taiho Oncology, Inc.
- ENROLLING BY INVITATIONPhase 2NCT04093570A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)Taiho Oncology, Inc.
- RECRUITINGPhase 2NCT03999723Combining Active and Passive DNA HypomethylationKirsten Grønbæk · PI: Kirsten Grønbæk, Prof., MD
- RECRUITINGPhase 1NCT04024761A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationDana-Farber Cancer Institute · PI: Susanne Baumeister, MD
- RECRUITINGPHASE1, PHASE2NCT03850574Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaAptose Biosciences Inc. · PI: Naval Daver, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03672539Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · PI: Yesid Alvarado-Valero, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03613532Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNJacqueline Garcia, MD · PI: Jacqueline S. Garcia, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03289910Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaNational Cancer Institute (NCI) · PI: Keith W Pratz
- RECRUITINGPhase 2NCT03383575Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeM.D. Anderson Cancer Center · PI: Courtney DiNardo
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02935361Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedUniversity of Southern California · PI: Casey O'Connell